Abstract
Etanercept is singular among anti-tumor necrosis factor alpha (TNF-α) agents, for being a soluble antibody to both TNF and lymphtoxin-alpha. The long-term neutralization of two cachexins by etanercept would theoretically compromise early detection of malignancy. This case reports a patient who was treated by etanercept for 21 months due to ankylosing spondylitis. Metastatic malignancy of unknown origin developed, and silently led the patient to lethal hepatic rupture. With an example of a malignancy masking effect of soluble TNF receptor, this article questions a need for vigilant attention to de novo carcinoma during the therapy, and calls for refined strategies in modulating autoimmune diseases.
This is a preview of subscription content, log in via an institution to check access.
References
Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72(9):3666–3670
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19):2275–2285
Geborek P, Bladström A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64(5):699–703
Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundstrom C, Bertilsson L, Coster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapaa-Dahlqvist S, Saxne T, Klareskog L, Feltelius N (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64(10):1414–1420
Hansen AM, Caspi RR (2009) Targeting lymphotoxin depletes pathogenic T cells. Nat Med 15(7):732–733
Mitch WE, Goldberg AL (1996) Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 335(25):1897–1905
Staal-van den Brekel AJ, Dentener MA, Schols AM, Buurman WA, Wouters EF (1995) Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 13(10):2600–2605
Chiang EY, Kolumam GA, Yu X, Francesco M, Ivelja S, Peng I, Gribling P, Shu J, Lee WP, Refino CJ, Balazs M, Paler-Martinez A, Nguyen A, Young J, Barck KH, Carano RA, Ferrando R, Diehl L, Chatterjea D, Grogan JL (2009) Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 15(7):766–773
Acknowledgments
Ethics approval and an informed consent were obtained.
Disclosures
None
Author information
Authors and Affiliations
Corresponding author
Additional information
Key Message
The long-term therapy with anti-tumor necrosis factor is apt to compromise the detection of malignancy.
Rights and permissions
About this article
Cite this article
Ahn, I.E., Ju, J.H., Kang, K.Y. et al. The silent progression of metastatic malignancy during the treatment with soluble tumor necrosis factor receptor. Clin Rheumatol 29, 225–227 (2010). https://doi.org/10.1007/s10067-009-1306-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-009-1306-9